PITCH & MATCH
Through Pitch & Match, we provide our investors and presenting companies the opportunity to get to know each other before event day, get engaged through presentation, Q&A and arrange immediate follow-up meetings.
Presentation fees: $3000 （Includes presentation fee and one registration for presenter）
Presentation Companies Can:
– Meet pre-vetted decision makers from top Chinese pharma and investment firms
– Know your audience prior to the pitch
– Maximized your company visibility through pre-conference promotion
– Present for 8min with Powerpoint
– Schedule immediate follow-up meetings through on-target partnering
Who Should Apply
- Biotech
- Drug development
- Platform technology
- Medical device
- Digital health
- Synthetic biology
- Research tools
Opportunities our audience are seeking
- Equity Investment
- Licensing
- Co-Development
- M&A
- Joint Venture
- And more…
Presentation fees: $3000 （Includes presentation fee and one registration for presenter）
Presenting companies will receive
-
Free consultation on 1-on-1 partnering
-
Receive a list of featured audience and their partnering demand prior to the event day
-
Pre-conference promotion to all conference attendees
-
8-min PowerPoint presentation during the conference
-
Immediate follow-up meetings through on-target partnering
Hengrui Pharmaceuticals
Description: A leading biopharmaceutical company based in China with annual sales of $2.2 billion in 2017 and a market cap of $31 billion.
Recent Deal: Mycovia and Hengrui Medicine have signed an agreement to develop and commercialise the former’s investigational drug, VT-1161 for RVVC
Interests: oncology, autoimmune, metabolic and CV
CSPC
Description: CSPC was recognized as the top brand for its compliance culture, ethical business and innovation
Recent Deal: Verastem grants CSPC exclusive rights to develop and commercialize the cancer drug Copiktra duvelisib in China.
Interests: Oncology, CV, Autoimmune
Fosun Pharma
Description: Established innovative chemical drugs platform, biologics platform, high-value generic drugs platform and cell-therapy platform.
Recent Deal: Revance Therapeutics grants Fosun exclusive Chinese rights to RT002.
Interests: oncology, cardiovascular disease, CNS, liver disease, medical device
Salubris Pharmaceuticals
Description: Salubris is a globally integrated pharmaceutical group dedicated to the research, development, manufacture, marketing, distribution.
Recent Deal: Viracta Therapeutics Inc. granted Salubris exclusive rights to develop and sell its virus-related cancer therapy nanatinostat/valganciclovir in the great China.
Interests: Oncology, CV and metabolic diseases
Luye Pharma
Description: Luye Pharma is an international pharmaceutical company with a robust pipeline of 40 drug candidates in China and more than 10 drug candidates overseas.
Recent Deal: Luye Pharma and PharmaMar Sign Licensing Agreement for the Development and Commercialization of Zepsyre® in China.
Interests: Oncology, CNS, CV, diabetes, digestive disease and metabolic diseases
Huadong Medicine
Description: A fully integrated pharmaceutical company focused on discovery, development, manufacturing and commercialization of medicines, with annual revenue of 4.5 billion USD.
Recent Deal: Huadong Medicine Co Ltd. Gains Access to Sinclair Pharma’s Highly Differentiated Aesthetics Products to Expand Business Beyond China into United States and Other Markets
Interests: Diabetes, Aesthetics, autoimmune disease, digestive disease, CV, oncology, and infectious disease.